Absolute bioavailability of oral immediate and slow release fluphenazine in healthy volunteers

1996 ◽  
Vol 51 (2) ◽  
pp. 183-187 ◽  
Author(s):  
R. Koytchev ◽  
R.-G. Alken ◽  
G. McKay ◽  
T. Katzarov
Keyword(s):  
Healthy Volunteers ◽  
Slow Release ◽  
Absolute Bioavailability

No Effect Of Persantin On Platelet Aggregation And Plasma βTg Levels In Healthy Volunteers

1981 ◽  
Author(s):  
A W A Lensing ◽  
A Sturk ◽  
J W ten Cate
Keyword(s):  
Side Effects ◽  
Healthy Volunteers ◽  
Cerebrovascular Accident ◽  
Slow Release ◽  
Double Blind Study ◽  
Prolonged Administration ◽  
Double Blind ◽  
Normal Limits ◽  
Induced Aggregation ◽  
Release Form

Previous studies from our laboratory revealed no effect of aspirin on plasma βTG levels in healthy volunteers as well as in patients with cerebrovascular accident. This double blind study was undertaken to investigate the effect of prolonged administration of Persantin. Two groups of 10 volunteers each received 4×100 mg Persantin or 2×200 mg daily in slow release form for 21 days. Platelet studies were performed prior to- and once every week during the trial. The volunteers refrained from smoking and were not on oral contraceptives or other drugs. No effect was observed on ADP (1 μ M f.c.) or collagen induced aggregation. All βTG plasma levels were within normal limits i.e. below 60/ml of plasma. No tendency of decreasing levels was observed. Side effects were significantly more observed in the volunteers on slow release Persantin (Mean Whitney Test α < 0.025). Side effects included sensations of a dry mouth and thirst, headache and di2Lzyness.

Effect of a slow-release formula of trimoprostil on intragastric acidity in healthy volunteers

2007 ◽  
Vol 2 (2) ◽  
pp. 135-141 ◽  
Author(s):  
C. EMDE ◽  
T. CILLUFFO ◽  
P. BAUERFEIND ◽  
C. J. FIMMEL ◽  
A. L. BLUM
Keyword(s):  
Healthy Volunteers ◽  
Slow Release ◽  
Intragastric Acidity

Absolute Bioavailability of Ceftriaxone after Intramuscular Administration to Healthy Volunteers

Chemotherapy ◽  
1983 ◽  
Vol 29 (3) ◽  
pp. 157-162 ◽  
Author(s):  
R. Delsignore ◽  
C.M. Baroni ◽  
G. Crotti ◽  
F. Mineo ◽  
U. Butturini ◽  
...  
Keyword(s):  
Healthy Volunteers ◽  
Intramuscular Administration ◽  
Absolute Bioavailability

INVESTIGATION OF DOSE PROPORTIONALITY AND ABSOLUTE BIOAVAILABILITY OF BROFAROMINE IN HEALTHY VOLUNTEERS

1992 ◽  
Vol 15 ◽  
pp. 430B ◽  
Author(s):  
K. H. Antonin ◽  
K. Kucher ◽  
L. Fuchs ◽  
P. R. Bieck ◽  
E. Schmidt
Keyword(s):  
Healthy Volunteers ◽  
Dose Proportionality ◽  
Absolute Bioavailability

scholarly journals The Influence of food on the bioavailability of slow-release metoprolol tartrate 120mg tablet in healthy volunteers and serum protein binding of metoprolol.

1991 ◽  
Vol 6 (4) ◽  
pp. 573-578
Author(s):  
Hidetoshi SHIMIZU ◽  
Hideyo NOGUCHI ◽  
Masakazu TAKASHIMA ◽  
Takahiro HIGASHIO ◽  
Junichi AZUMA ◽  
...  
Keyword(s):  
Protein Binding ◽  
Healthy Volunteers ◽  
Serum Protein ◽  
Slow Release ◽  
Metoprolol Tartrate ◽  
Serum Protein Binding ◽  
Influence Of Food

Comparative Pharmacokinetics of 400 mg Bezafibrate after a Single Oral Administration of a New Slow-Release Preparation and the Currently Available Commercial Form

1981 ◽  
Vol 9 (6) ◽  
pp. 516-520 ◽  
Author(s):  
H Ledermann ◽  
B Kaufmann
Keyword(s):  
Serum Concentration ◽  
Healthy Volunteers ◽  
Slow Release ◽  
Lipid Lowering ◽  
Release Preparation ◽  
Single Oral Administration ◽  
Lipid Lowering Agent ◽  
Objective Side ◽  
Slow Release Preparation ◽  
Concentration Curves

Bezafibrate is a new lipid-lowering agent with a more pronounced pharmacological effect, a different metabolism and a much shorter apparent half-life than clofibrate. The serum concentration curves and the urinary excretion were determined in seventeen healthy volunteers after administration of 400 mg of a new slow-release preparation. The results were compared with those of a similar experiment in twenty healthy volunteers who received 400 mg as a single dose in the form of 2 tablets of Cedur®, which is the currently marketed form in Germany (each tablet contains 200 mg bezafibrate). The areas under the serum concentration curves were not statistically significantly different (median of 31.3 mg.h/l for the slow-release and of 39.4 mg.h/l for the marketed preparation). Renal clearance differed only within the margin of biological variation. It can be assumed that the relative biological availability of both preparations is similar. In none of the volunteers were subjective or objective side-effects observed.

Sign in / Sign up

Export Citation Format

Share Document